Back to News
Market Impact: 0.42
Wedbush Reaffirms Outperform Rating On Pharvaris; PT $42 After Positive Phase 3 CHAPTER-3 Data
Source: Nasdaq
Healthcare & BiotechAnalyst InsightsCompany Fundamentals
Wedbush reiterated its Outperform rating and $42 12-month price target for Pharvaris after the pivotal Phase 3 CHAPTER-3 trial of deucrictibant XR met its primary endpoint and all secondary efficacy endpoints. The positive late-stage clinical readout materially supports the company’s drug-development outlook and investment case.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
PHVS0.86
More News
- Here’s the ‘core economic flaw’ in the AI bull case as stock and bond trades unravel, according to a top economist
- How Pepsi fell behind in the cola wars—and then lost KFC
- 5 big analyst AI moves: ’Uniquely catalyst-rich’ months ahead for SpaceX
- Braskem creditors, shareholders near deal on $11bn debt restructuring
- Xencor reports phase 1 data for cancer drug XmAb819
- The experience economy keeps defying expectations. Maybe we’ve been looking at it all wrong